fashion -WSS

fashion

author：focus 2025-09-14 21:59:54 - browse：432

JOSEPH PREZIOSO/AFP via Getty Images

Late-stage trial results for a pain medication developed by Vertex Pharmaceuticals reinforced experts’ sense that the drug was both safe and offered modest pain relief. But the findings also prompted fresh debate on Tuesday about how widely used the therapy would be should it win regulatory approval.

The company reported that its small molecule drug, VX-548, outperformed placebo in a pair of pain relief trials that recruited patients who had gotten an abdominoplasty (tummy tuck) or bunion surgery. The study also found that the drug was generally safe, with fewer patients on the medication reporting adverse events than those who had taken a placebo. But there was a catch: VX-548 didn’t outperform a combination of acetaminophen and the opioid hydrocodone, a key secondary endpoint. And in the bunionectomy study, the opioid comparator beat VX-548 on pain relief.

“While this study was not explicitly designed to test VX-548 vs. the opioid comparator, this may complicate the prescribing decision in the acute setting, where patients often take a short course of treatment and efficacy is a primary consideration,” Stifel market analyst Paul Matteis wrote in a note to investors, adding that results from three Phase 3 studies were positive overall.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： George Santos makes 1st court appearance after pleading not guilty to 13 counts
Next article： Deliver public health messages at the right time

WSS

Deliver public health messages at the right time

Does aspartame cause cancer? What new WHO guidance says

Crowdfunding for medical bills sidesteps core problem, author says

Most antidepressants don't work on kids, teens, study finds

Eli Lilly to acquire Versanis in heated race for weight loss drugs

Congress: Eradicate hepatitis C and reduce the deficit

focus

fashion

hotspot

In Memoriam: Notable people who died in 2023

Celiac disease study examines precisely how gluten triggers injury

What does generative AI mean for health care? We asked experts

J&J expands global access to TB drug amid advocacy campaign

Apple is now the first public company to be valued at $3 trillion

How a small hospital in rural Puerto Rico survived Hurricane Maria

Duchenne breakthrough therapy leaves behind pioneering families

Readout Newsletter: PTC, Dyne, Rapport, Cytokinetics news

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

AI for drug discovery: Experts on separating hype from reality

Wikipedia

As health system earnings go up, health insurance stocks go down

Empower primary care with adequate payments and technology

Welsh Carson private equity firm escapes from FTC antitrust case

Elon Musk says Twitter has 'negative cash flow' and 'heavy debt'

Who gets to use the title 'doctor'?

PBM executives asked to testify by House panel

leisure time

entertainment

leisure time

focus